United States · biotech/health
United States · biotech/healthArcus Biosciences
Arcus Biosciences is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for the treatment of cancer.
Public · NYSE:RCUSFor profit
Against its peers
Set against 435 biotech/health companies in United States. The ring marks the typical peer.
Across all 5.9M companies: larger than 85% of those with a size listed; older than 5% of those with a founding year; website ranked #1,995,173 in the world, about 10k visits a month.
About Arcus Biosciences
BiopharmaBiotechnologyClinical TrialsHealth CareMedicalPharmaceuticalTherapeutics
Funding, as listed
What the source datasets report. We have not watched these rounds ourselves.
$967M
raised in total, currency not stated across 6 rounds
Last raised Jan 2024, 2 years ago
- Rounds
- 6
- Latest round
- Post ipo equity
- Investors
- 182 leading
Key facts
Who started it and how it trades.
- Founded by
- Juan Jaen, Terry Rosen
Every detail we hold
Everything the source datasets list about Arcus Biosciences, field by field. Contact details are held but never shown.
The company7 fields
- Name
- Arcus Biosciences
- Type
- For profit
- Status
- Public · NYSE:RCUS
- Founded
- 2015
- Founders
- Juan Jaen, Terry Rosen
- Industry
- biotech/health
- Categories
- Biopharma, Biotechnology, Clinical Trials, Health Care, Medical, Pharmaceutical, Therapeutics
Where3 fields
- City
- Hayward
- Country
- United States
- Markets
- San Francisco Bay Area, Silicon Valley, West Coast, Western US
Size and reach3 fields
- Staff band
- 101-250
- Web traffic rank
- #1,995,173
- Monthly web visits
- 10,494
Show 10 more fieldsShow fewer fields
Funding, as listed8 fields
- Total
- 967,050,000 (currency not stated)
- Rounds
- 6
- Latest round
- Post ipo equity
- Latest round date
- Jan 2024
- Investors
- 18
- Lead investors
- 2
- Stock listing
- NYSE:RCUS
- Listing status
- public
About this record2 fields
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Arcus Biosciences reported earnings last week, leading analysts to upgrade their estimates. Gilead Sciences increased its stake in Arcus Biosciences to 33% and announced an amended collaboration and equity investment. Gilead also stopped a phase 3 TIGIT trial but invested $320 million into Arcus Biosciences. Arcus Biosciences beat expectations in its first quarter 2024 earnings.
Companies like Arcus Biosciences
biotech/health in United States.
Revolution MedicinesRedwood City · 251-500 peoplefounded the same year
FreenomeSouth San Francisco · 501-1000 peoplefounded 1 years earlier
Relay TherapeuticsCambridge · 251-500 peoplefounded 1 years later
Denali TherapeuticsSan Francisco · 251-500 peoplefounded 2 years earlier
SpringWorks TherapeuticsStamford · 251-500 peoplefounded 2 years laterBuild a lead list
435 biotech/health companies in United States, filtered by size, age and reach, ready to export with emails on Pro.